Literature DB >> 12600857

Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: a randomized placebo-controlled study.

Bernard J Venn1, Timothy J Green, Rudolf Moser, Jim I Mann.   

Abstract

BACKGROUND: Food fortification with folic acid has been introduced in several countries for the prevention of neural tube defects. Fortification has lowered total homocysteine (tHcy) concentrations in the US population, a consequence that may have health benefits. However, folic acid fortification could mask vitamin B-12 deficiency. Synthetic L-5-methyltetrahydrofolate (L-MTHF) may be more appropriate than folic acid as a fortificant because it is unlikely to mask the hematologic indicators of vitamin B-12 deficiency.
OBJECTIVE: The objective of the study was to compare the effectiveness of 100 micro g folic acid/d with that of equimolar L-MTHF in lowering tHcy in healthy volunteers.
DESIGN: The study was designed as a 24-wk, randomized, placebo-controlled intervention. Free-living healthy volunteers (n = 167) were randomly assigned to receive a daily supplement containing folic acid (100 microg), L-MTHF (113 microg), or placebo. Blood collected at baseline and at 8, 16, and 24 wk was analyzed for tHcy, plasma folate, and red blood cell folate (RCF) concentrations.
RESULTS: At 24 wk, after adjustment for baseline values, mean (95% CI) tHcy was 14.6% (9.3, 19.5%) and 9.3% (3.7, 14.6%) lower, mean plasma folate was 34% (14, 56%) and 52% (30, 78%) higher, and mean RCF was 23% (12, 35%) and 31% (19, 44%) higher in the L-MTHF and folic acid groups, respectively, than in the placebo group. L-MTHF was more effective than was folic acid in lowering tHcy (P < 0.05). At 24 wk, the increases in plasma folate and RCF concentrations did not differ significantly between the 2 supplemented groups.
CONCLUSION: Low-dose L-MTHF is at least as effective as is folic acid in reducing tHcy concentrations in healthy persons.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12600857     DOI: 10.1093/ajcn/77.3.658

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  16 in total

Review 1.  Effects and safety of periconceptional folate supplementation for preventing birth defects.

Authors:  Luz Maria De-Regil; Ana C Fernández-Gaxiola; Therese Dowswell; Juan Pablo Peña-Rosas
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

Review 2.  Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics.

Authors:  Klaus Pietrzik; Lynn Bailey; Barry Shane
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

3.  Active Folate Versus Folic Acid: The Role of 5-MTHF (Methylfolate) in Human Health.

Authors:  Lorena Carboni
Journal:  Integr Med (Encinitas)       Date:  2022-07

4.  Conversion of calcium-l-methylfolate and (6S)-5-methyltetrahydrofolic acid glucosamine salt into dietary folate equivalents.

Authors:  Dominique Turck; Torsten Bohn; Jacqueline Castenmiller; Stefaan De Henauw; Karen Ildico Hirsch-Ernst; Helle Katrine Knutsen; Alexandre Maciuk; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Carmen Peláez; Alfonso Siani; Frank Thies; Sophia Tsabouri; Marco Vinceti; Francesco Cubadda; José Cortiñas Abrahantes; Céline Dumas; Valeria Ercolano; Ariane Titz; Kristina Pentieva
Journal:  EFSA J       Date:  2022-08-24

5.  Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone.

Authors:  Herbert Wiesinger; Urte Eydeler; Frank Richard; Dietmar Trummer; Hartmut Blode; Beate Rohde; Konstanze Diefenbach
Journal:  Clin Drug Investig       Date:  2012-10-01       Impact factor: 2.859

6.  EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation.

Authors:  Konstanze Diefenbach; Dietmar Trummer; Frank Ebert; Michael Lissy; Manuela Koch; Beate Rohde; Hartmut Blode
Journal:  Int J Womens Health       Date:  2013-04-11

7.  Folate status of reproductive age women and neural tube defect risk: the effect of long-term folic acid supplementation at doses of 140 µg and 400 µg per day.

Authors:  Nicola A Hursthouse; Andrew R Gray; Jody C Miller; Meredith C Rose; Lisa A Houghton
Journal:  Nutrients       Date:  2011-01-10       Impact factor: 6.706

8.  Preliminary evidence for cell membrane amelioration in children with cystic fibrosis by 5-MTHF and vitamin B12 supplementation: a single arm trial.

Authors:  Cinzia Scambi; Lucia De Franceschi; Patrizia Guarini; Fabio Poli; Angela Siciliano; Patrizia Pattini; Andrea Biondani; Valentina La Verde; Oscar Bortolami; Francesco Turrini; Franco Carta; Ciro D'Orazio; Baroukh M Assael; Giovanni Faccini; Lisa M Bambara
Journal:  PLoS One       Date:  2009-03-11       Impact factor: 3.240

Review 9.  Effects and safety of periconceptional oral folate supplementation for preventing birth defects.

Authors:  Luz Maria De-Regil; Juan Pablo Peña-Rosas; Ana C Fernández-Gaxiola; Pura Rayco-Solon
Journal:  Cochrane Database Syst Rev       Date:  2015-12-14

10.  The SU.FOL.OM3 Study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or Omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics.

Authors:  Pilar Galan; Serge Briancon; Jacque Blacher; Sébastien Czernichow; Serge Hercberg
Journal:  Trials       Date:  2008-06-10       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.